June, 2024
June 2024
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
David Sebag-Montefiore: From the CRUK RadNet Leeds renewal interview to the ESTRO 2024 annual meeting
May 11, 2024, 10:48

David Sebag-Montefiore: From the CRUK RadNet Leeds renewal interview to the ESTRO 2024 annual meeting

David Sebag-Montefiore shared on LinkedIn:

“It’s been a very exciting week! From the CRUK RadNet Leeds renewal interview at Cancer Research UK (CRUK) Head Office in London to the European Society for Radiotherapy and Oncology (ESTRO) 2024 annual meeting in Glasgow!

It was great to work with our fantastic RadNet Leeds team – Ane Appelt, Ann Henry, Andrew Macdonald, Adel Samson, Nick West and Danni Battle.

It was fabulous to present our RadNet Leeds science at ESTRO and meet up with colleagues from across the globe. Closer to home, a real highlight was the Leeds ESTRO team dinner. I am really proud to work with such a wonderful, friendly and talented group of people!”

David Sebag-Montefiore

Source: David Sebag-Montefiore/LinkedIn

David Sebag-Montefiore is the Audrey and Stanley Burton Professor of Clinical Oncology at the University of Leeds and Honorary Clinical Oncologist at Leeds Teaching Hospitals NHS Trust.

He serves as the Clinical Director of Leeds Cancer Research Centre, Director of the Leeds Cancer Research UK Radiotherapy Research Centre of Excellence, and Clinical Director of the Leeds Cancer Research UK Clinical Trials Unit. He Chairs the National Cancer Institute Radiotherapy Research Group (CTRad) and previously chaired Cancer Research UK’s Clinical Trials Awards and Advisory Committee (CTAAC).
OncoDaily
Dr. Sebag-Montefiore’s research interests focus on personalized and adaptive radiotherapy including novel agent radiotherapy combinations through interdisciplinary research including artificial intelligence, computational modeling data science, and imaging to improve patient outcomes. As chief investigator of randomised clinical trials his research has determined standards of care internationally for patients with anal and rectal cancer. His current interests include novel and adaptive radiotherapy platform trials.